Literature DB >> 1373595

In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism.

S H Vincent1, B V Karanam, S K Painter, S H Chiu.   

Abstract

The metabolism of the immunosuppressant FK-506 was shown to be catalyzed primarily by cytochrome P450 isozymes of the P450 3A subfamily. Antibodies against rat P450 3A inhibited FK-506 metabolism by 82% in rat liver microsomes and by 35-56% in liver microsomes from humans, dexamethasone-induced rats, and erythromycin-induced rabbits. Poor species cross-reactivity of the antibodies, metabolic switching, and/or some metabolism by P450 isozymes other than P450 3A may be responsible for the incomplete inhibition observed. Besides anti-rat P450 3A, antibodies against rat P450 1A also appeared to have some inhibitory effect implicating these particular cytochrome P450 isozymes as having a minor role in FK-506 metabolism. The formation of 13-desmethyl FK-506, identified here as a major metabolite of FK-506 in all types of microsomes examined, was inhibited completely by anti-P450 3A in liver microsomes from dexamethasone-induced rats and erythromycin-induced rabbits but only partially in human and control rat liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373595     DOI: 10.1016/0003-9861(92)90711-5

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  26 in total

1.  Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation: a case report.

Authors:  Gaëlle Hardy; Françoise Stanke-Labesque; Claudine Contamin; Françoise Serre-Debeauvais; François Bayle; Philippe Zaoui; Germain Bessard
Journal:  Eur J Clin Pharmacol       Date:  2004-09-15       Impact factor: 2.953

Review 2.  Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations.

Authors:  Simon Tremblay; Rita R Alloway
Journal:  AAPS J       Date:  2017-07-17       Impact factor: 4.009

3.  Interaction between FK 506 and clarithromycin in a renal transplant patient.

Authors:  K Wolter; K Wagner; T Philipp; E Fritschka
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.

Authors:  Markus Bickel; Evrim Anadol; Martin Vogel; Wolf Peter Hofmann; Nils von Hentig; Johannes Kuetscher; Michael Kurowski; Christian Moench; Tessa Lennemann; Thomas Lutz; Wolf Otto Bechstein; Hans Reinhard Brodt; Jürgen Rockstroh
Journal:  J Antimicrob Chemother       Date:  2010-03-04       Impact factor: 5.790

5.  Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance.

Authors:  Marie Antignac; Jean Sebastien Hulot; Emmanuel Boleslawski; Laurent Hannoun; Yvan Touitou; Robert Farinotti; Philippe Lechat; Saïk Urien
Journal:  Eur J Clin Pharmacol       Date:  2005-07-01       Impact factor: 2.953

6.  The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.

Authors:  Kelly A Birdwell; Ben Grady; Leena Choi; Hua Xu; Aihua Bian; Josh C Denny; Min Jiang; Gayle Vranic; Melissa Basford; James D Cowan; Danielle M Richardson; Melanie P Robinson; Talat Alp Ikizler; Marylyn D Ritchie; Charles Michael Stein; David W Haas
Journal:  Pharmacogenet Genomics       Date:  2012-01       Impact factor: 2.089

7.  Tacrolimus analysis: a comparison of different methods and matrices.

Authors:  V Warty; S Zuckerman; R Venkataramanan; J Lever; J Chao; T Mckaveney; J Fung; T Starzl
Journal:  Ther Drug Monit       Date:  1995-04       Impact factor: 3.681

8.  Microbial Demethylation of Immunosuppressant FK-506: Isolation of 31-O-FK-506-Specific Demethylase Showing Cytochrome P-450 Characteristics from Streptomyces rimosus MA187.

Authors:  A Shafiee; T Chen; P Cameron
Journal:  Appl Environ Microbiol       Date:  1995-10       Impact factor: 4.792

9.  Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Samer K Khaled; Joycelynne M Palmer; Josef Herzog; Tracey Stiller; Ni-Chun Tsai; David Senitzer; Xueli Liu; Sandra H Thomas; Sepideh Shayani; Jeffrey Weitzel; Stephen J Forman; Ryotaro Nakamura
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-30       Impact factor: 5.742

Review 10.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.